Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.
Current Value
$17.061 Year Return
Current Value
$17.061 Year Return
Market Cap
$249.56M
P/E Ratio
-2.57
1Y Stock Return
-17.52%
1Y Revenue Growth
0.52%
Dividend Yield
0.00%
Price to Book
1.4
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DECK | 0.01% | $26.78B | +66.79% | 0.00% |
CNC | 0.08% | $29.19B | -21.56% | 0.00% |
HIHO | 0.08% | $8.63M | 0.00% | 6.12% |
SYK | 0.08% | $148.17B | +32.36% | 0.82% |
SAVA | 0.09% | $1.35B | +25.50% | 0.00% |
FOXF | 0.10% | $1.33B | -47.63% | 0.00% |
HLIO | -0.11% | $1.68B | +26.81% | 0.72% |
NXE | -0.14% | $4.79B | +29.91% | 0.00% |
ERIE | 0.15% | $19.39B | +46.23% | 1.23% |
ASPS | 0.15% | $22.36M | -80.26% | 0.00% |
BCAN | 0.15% | $72.87M | -99.75% | 0.00% |
ARRY | 0.18% | $926.85M | -60.03% | 0.00% |
NMM | -0.19% | $1.58B | +126.51% | 0.38% |
ERII | 0.21% | $888.67M | -20.30% | 0.00% |
GEV | 0.22% | $93.72B | +159.05% | 0.00% |
MAGN | -0.23% | $638.97M | -3.42% | 0.00% |
NIU | 0.28% | $126.87M | -28.79% | 0.00% |
BNED | 0.32% | $277.22M | -91.94% | 0.00% |
BTCT | 0.33% | $42.61M | +353.33% | 0.00% |
VHC | 0.34% | $19.06M | -38.36% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
UUU | -41.86% | $4.97M | -41.89% | 0.00% |
ETR | -38.66% | $32.14B | +49.00% | 3.05% |
PAYC | -35.45% | $12.12B | +21.78% | 0.69% |
ROOT | -32.37% | $1.53B | +972.93% | 0.00% |
MO | -28.60% | $94.67B | +37.05% | 7.07% |
ATEC | -27.14% | $1.36B | -16.49% | 0.00% |
MATX | -26.68% | $5.07B | +59.09% | 0.86% |
RELY | -23.72% | $3.96B | -7.42% | 0.00% |
IP | -23.55% | $20.09B | +78.02% | 3.20% |
MCS | -22.91% | $669.85M | +49.35% | 1.28% |
SXC | -22.39% | $1.05B | +39.93% | 3.52% |
TK | -22.17% | $728.26M | +11.06% | 0.00% |
TWLO | -21.75% | $14.78B | +54.09% | 0.00% |
NXT | -21.35% | $5.23B | -7.21% | 0.00% |
CSV | -20.60% | $590.66M | +75.49% | 1.16% |
SCI | -18.87% | $12.43B | +42.31% | 1.39% |
AME | -18.54% | $44.75B | +24.49% | 0.56% |
MDGL | -17.24% | $6.85B | +66.72% | 0.00% |
IMAX | -17.20% | $1.31B | +51.92% | 0.00% |
LPLA | -17.17% | $23.55B | +38.13% | 0.38% |
SeekingAlpha
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ETCompany ParticipantsMatt Hall - Director, Corporate...
Yahoo
Anika Therapeutics ( NASDAQ:ANIK ) Third Quarter 2024 Results Key Financial Results Revenue: US$38.8m (down 6.5% from...
Yahoo
Anika Therapeutics Inc (ANIK) navigates revenue challenges with a focus on HA-based products and international growth.
Yahoo
Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ: ANIK). Two former Arthrosurface leaders joined the Primo Medical Group executives in this strategic acquisition which ensures that Arthrosurface's position as a leader in orthopedic joint preservation solutions will resume with its portfolio of innovative products and expe
Yahoo
Anika (ANIK) delivered earnings and revenue surprises of -183.33% and 8.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
ANIK) on Thursday reported a loss of $29.9 million in its third quarter. On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of $2.03. Losses, adjusted for asset impairment costs and stock option expense, were 25 cents per share.
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HII | 54.74% | $7.50B | -19.92% | 2.70% |
SRI | 50.33% | $166.13M | -63.46% | 0.00% |
ARW | 46.41% | $5.98B | -5.69% | 0.00% |
APTV | 44.40% | $12.25B | -35.53% | 0.00% |
NVRI | 44.26% | $552.13M | +20.03% | 0.00% |
RCKY | 43.67% | $155.86M | -17.74% | 2.95% |
SMHI | 42.84% | $176.10M | -44.22% | 0.00% |
NSIT | 42.69% | $4.75B | -0.16% | 0.00% |
MG | 41.91% | $282.81M | +42.06% | 0.00% |
OTEX | 40.93% | $7.59B | -26.30% | 3.55% |
SNN | 40.72% | $11.12B | -0.04% | 2.98% |
AROW | 40.54% | $546.36M | +34.05% | 4.19% |
TFX | 40.50% | $8.97B | -10.85% | 0.71% |
GEL | 40.07% | $1.44B | +2.81% | 5.24% |
JBSS | 39.95% | $949.98M | -9.36% | 1.04% |
ACEL | 39.79% | $940.36M | +12.85% | 0.00% |
EL | 39.72% | $23.26B | -46.08% | 4.10% |
FOLD | 39.50% | $2.84B | -11.52% | 0.00% |
REGN | 39.21% | $81.82B | -6.79% | 0.00% |
EPAM | 38.45% | $12.91B | -11.78% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -22.04% | $388.04M | 1.43% |
VIXY | -20.94% | $195.31M | 0.85% |
CTA | -16.95% | $350.27M | 0.78% |
TAIL | -12.17% | $67.98M | 0.59% |
USDU | -11.17% | $201.97M | 0.5% |
FMF | -10.59% | $244.61M | 0.95% |
EQLS | -10.38% | $76.08M | 1% |
TBIL | -9.46% | $4.38B | 0.15% |
KRBN | -9.42% | $242.47M | 0.85% |
DBMF | -9.16% | $1.02B | 0.85% |
DBO | -8.25% | $217.57M | 0.77% |
UUP | -8.12% | $309.25M | 0.77% |
DBE | -7.92% | $50.13M | 0.77% |
MINT | -7.72% | $11.62B | 0.35% |
HDRO | -6.75% | $164.26M | 0.3% |
XHLF | -6.24% | $874.27M | 0.03% |
KMLM | -5.99% | $353.87M | 0.9% |
KCCA | -5.99% | $220.51M | 0.87% |
BILZ | -5.42% | $563.02M | 0.14% |
XBIL | -5.28% | $637.70M | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FTGC | 0.09% | $2.17B | 1.02% |
AGZD | -0.10% | $142.76M | 0.23% |
URNM | -0.16% | $1.61B | 0.75% |
WEAT | 0.29% | $120.27M | 0.28% |
IBDP | 0.34% | $2.11B | 0.1% |
DBC | -0.47% | $1.39B | 0.87% |
FBY | -0.59% | $127.69M | 0.99% |
PDBC | -1.23% | $4.40B | 0.59% |
USCI | -1.43% | $185.47M | 1.07% |
SEIX | 1.63% | $268.81M | 0.62% |
ULST | 1.81% | $535.47M | 0.2% |
URNJ | 1.88% | $283.55M | 0.8% |
IBTE | 2.55% | $1.70B | 0.07% |
BCD | 2.65% | $245.02M | 0.3% |
TBLL | -2.89% | $1.92B | 0.08% |
UNG | -2.93% | $908.80M | 1.06% |
SGOV | -2.97% | $27.53B | 0.09% |
COMT | -3.13% | $829.06M | 0.48% |
GSG | -3.14% | $914.42M | 0.75% |
PHDG | 3.46% | $113.97M | 0.39% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FBT | 37.89% | $1.11B | 0.56% |
ISCG | 36.75% | $640.00M | 0.06% |
ESML | 36.21% | $1.90B | 0.17% |
REGL | 36.20% | $1.65B | 0.4% |
FALN | 36.07% | $1.84B | 0.25% |
EFAA | 36.05% | $117.38M | 0% |
PSC | 35.87% | $702.17M | 0.38% |
XSHD | 35.81% | $54.49M | 0.3% |
RWJ | 35.79% | $1.75B | 0.39% |
NUSC | 35.74% | $1.27B | 0.31% |
QQA | 34.37% | $135.01M | 0% |
IBHG | 33.46% | $175.24M | 0.35% |
NUHY | 32.95% | $89.47M | 0.31% |
XBI | 32.23% | $6.58B | 0.35% |
IWC | 32.21% | $933.99M | 0.6% |
XSLV | 32.00% | $322.27M | 0.25% |
IWN | 31.96% | $13.17B | 0.24% |
VTWO | 31.84% | $12.38B | 0.1% |
DES | 31.79% | $2.13B | 0.38% |
IJS | 31.70% | $7.37B | 0.18% |